Search reports, ask a question, or jump to a page.
The problem
Intervention: Universal newborn immunisation with nirsevimab (a long-acting monoclonal antibody) administered before hospital discharge
Who it was tested with: All infants born in the Mid-West region of Ireland between 1 September 2024 and 28 February 2025 (n=1,790).
Experience from people who deliver programmes: stories, case studies and lessons learned. Valuable for understanding how and why, and for spotting what to test next, but not a measure of effect.
"Cross-sectional analysis of routinely collected programme data" showing uptake rates and associated factors. This represents routine programme monitoring rather than an experimental evaluation of intervention efficacy; it demonstrates feasibility and identifies implementation patterns but does not measure whether the intervention prevents RSV disease.
This is an observational study without a comparison group, limited to one region and hospital, and does not measure health outcomes such as RSV infection rates or disease severity. The study does not investigate reasons for ethnic disparities or barriers to access.
Across countries and designs
6 studies · 17 countries
